Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin

Food and Chemical Toxicology

Volumn 45, Issue 11, 2007, Pages 2155-2164

  Shiu, L Y ^a   Chang, L C ^b   Liang, C H ^c   Huang, Y S ^a   Sheu, H M ^d   Kuo, K W ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Breast cancers; Cisplatin; Fas; Solamargine; TNF

Indexed keywords

ALKALOID; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME C; DEATH RECEPTOR; EPIRUBICIN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUOROURACIL; GLYCOSIDE; METHOTREXATE; MITOCHONDRIAL ENZYME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SOLAMARGINE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR I ASSOCIATED DEATH DOMAIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SENSITIZATION; SOLANUM; SOLANUM INCANUM; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INHIBITORY CONCENTRATION 50; SIGNAL TRANSDUCTION; SOLANACEOUS ALKALOIDS; UP-REGULATION;

SOLANUM INCANUM;

EID: 34548822397     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2007.05.009     Document Type: Article

References (41)

1. Aiello A., Delia D., Borrello M.G., Biassoni D., Giardini R., Fontanella E., Pezzella F., Pulford K., Pierotti M., and Della Porta G. Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry 13 (1992) 502-509
2. Alzerreca A., and Hart G. Molluscicidal steroid glycoalkaloids possessing stereoisomeric spirosolane structures. Toxicol. Lett. 12 (1982) 151-155
3. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
4. Buchele T. Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)-review of preclinical and clinical results. Onkologie 7 (2003) 60-69
5. Choi H.J., Yee S.B., Park S.E., Im E., Jung J.H., Chung H.Y., Choi Y.H., and Kim N.D. Petrotetrayndiol A induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells through cytochrome c-mediated activation of caspases. Cancer Lett. 232 (2006) 214-225
6. Chouaib S., Thiery J., Gati A., Guerra N., El Behi M., Dorothee G., Mami-Chouaib F., Bellet D., and Caignard A. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60 (2002) 273-281
7. Chang L.C., Tsai T.R., Wang J.J., Lin C.N., and Kuo K.W. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochem. Biophys. Res. Commun. 242 (1998) 21-25
8. De Giorgi F., Lartigue L., Bauer M.K., Schubert A., Grimm S., Hanson G.T., Remington S.J., Youle R.J., and Ichas F. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J. 16 (2002) 607-609
9. De Vries E.G., Timmer T., Mulder N.H., van Geelen C.M., van der Graaf W.T., Spierings D.C., de Hooge M.N., Gietema J.A., and de Jong S. Modulation of death receptor pathways in oncology. Drugs Today 39 (2003) 95-109
10. Del Bello B., Valentini M.A., Zunino F., Comporti M., and Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 20 (2001) 4591-4595
11. Del Bufalo D., Biroccio A., Trisciuoglio D., Bruno T., Floridi A., Aquino A., and Zupi G. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur. J. Cancer 38 (2002) 2455-2462
12. Deming P.B., and Rathmell J.C. Mitochondria, cell death, and B cell tolerance. Curr. Dir. Autoimmun. 9 (2006) 95-119
13. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 (2005) 178-194
14. Gonzalez V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 59 (2001) 657-663
15. Gutierrez-Puente Y., Zapata-Benavides P., Tari A.M., and Lopez-Berestein G. Bcl-2-related antisense therapy. Semin. Oncol. 29 (2002) 71-76
16. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
17. Hartung L., and Bahler D.W. Flow cytometric analysis of Bcl-2 can distinguish small number of acute lymphoblastic leukaemia cells from B-cell precursors. Br. J. Haematol. 127 (2004) 50-58
18. Kuo K.W., Hu S.H., Li Y.P., Lin W.L., Liu L.F., Chang L.C., Lin C.C., Lin C.N., and Sheu H.M. Anticancer activity evaluation of the solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells. Biochem. Pharmacol. 60 (2000) 1865-1873
19. Lejeune F.J., Lienard D., Matter M., and Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 22 (2006) 6-22
20. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
21. Liang C.H., Liu L.F., Shiu L.Y., Huang Y.S., Chang L.C., and Kuo K.W. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem. Biophys. Res. Commun. 322 (2004) 751-758
22. Lin C.N., Lu C.M., Cheng M.K., Gan K.H., and Won S.J. The cytotoxic principles of Solanum incanum. J. Nat. Prod. 53 (1990) 513-516
23. Liu L.F., Liang C.H., Shiu L.Y., Lin W.L., Lin C.C., and Kuo K.W. Action of solamargine on human lung cancer cells-enhancement of the susceptibility of cancer cells to TNFs. FEBS Lett. 577 (2004) 67-74
24. Lorey S., Porzel A., and Ripperger H. Steroid alkaloid glycosides from Solanum coccineum. Phytochemistry 41 (1996) 1633-1635
25. Manion M.K., Fry J., Schwartz P.S., and Hockenbery D.M. Small-molecule inhibitors of Bcl-2. Curr. Opin. Invest. Drugs 7 (2006) 1077-1084
26. Mercatante D.R., Mohler J.L., and Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277 (2002) 49374-49382
27. Piro L.D. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston Park) 18 (2004) 5-10
28. Plas D.R., and Thompson C.B. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol. Metab. 13 (2002) 75-78
29. Ricci M.S., and Zong W.X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11 (2006) 342-357
30. Rudin C.M., Yang Z., Schumaker L.M., VanderWeele D.J., Newkirk K., Egorin M.J., Zuhowski E.G., and Cullen K.J. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 63 (2003) 312-318
31. Schneider P., and Tschopp J. Apoptosis induced by death receptors. Pharm. Acta. Helv. 74 (2000) 281-286
32. Sharma K., Wang R.X., Zhang L.Y., Yin D.L., Luo X.Y., Solomon J.C., Jiang R.F., Markos K., Davidson W., Scott D.W., and Shi Y.F. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol. Ther. 88 (2000) 333-347
33. Shimizu S., Eguchi Y., Kamiike W., Funahashi Y., Mignon A., Lacronique V., Matsuda H., and Tsujimoto Y. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc. Natl. Acad. Sci. USA 95 (1998) 1455-1459
34. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
35. Song R.X., and Santen R.J. Apoptotic action of estrogen. Apoptosis 8 (2003) 55-60
36. Thomas M., Wieland V., Heike S., Angelika F., Andrej B., Axel G., and Hans-Joachim S. Failure of activation of Caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 63 (2003) 513-521
37. Thorburn A. Death receptor-induced cell killing. Cell Signal 16 (2004) 139-144
38. Tortora G., Caputo R., Damiano V., Caputo R., Troiani T., Veneziani B.M., De Placido S., Bianco A.R., Zangemeister-Wittke U., and Ciardiello F. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. 9 (2003) 866-871
39. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J. Cell Physiol. 195 (2003) 158-167
40. Van Stijn A., Kok A., van der Pol M.A., Feller N., Roemen G.M., Westra A.H., Ossenkoppele G.J., and Schuurhuis G.J. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia 17 (2003) 780-786
41. Wei M.C., Zong W.-X., Cheng E.H.-Y., Lindsten T., Panousakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (Wash. DC) 292 (2001) 727-730